Setting new standards in information exchange for the pharmaceutical and biotech industry
Congratulations to Allergan’s Brent Saunders and David Nicholson, R&D Leadership 2015 Keynote Speakers, on Ringing the Opening Bell at the NY Stock Exchange
June 21, 2015
Allergan’s CEO, Brent Saunders and Dr David Nicholson, EVP, Brand R&D, both 2015 keynotes at the R&D Leadership Summit along with other company members had the honor to ring in the opening bell of the NY Stock Exchange earlier this week. They have much to celebrate with a new deal they are closing to add to their lineup of cosmetic medicines. They agreed to buy Kythera’s newly approved double-chin treatment in a $2.1 billion deal.